Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia

International Journal of Clinical Practice

Volumn 62, Issue 7, 2008, Pages 1026-1032

  Reviriego, J ^a   Gomis, R ^b   Maranes J P ^c   Ricart, W ^d   Hudson, P ^e   Sacristan J A ^a  

^a ELI LILLY AND COMPANY   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL JOSEP TRUETA   (Spain)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN DERIVATIVE; INSULIN LISPRO; INSULIN ZINC SUSPENSION;

ADOLESCENT; ADULT; ARTICLE; CAREGIVER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG COST; ENDOCRINOLOGY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION COST; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MEDICAL SPECIALIST; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SPAIN; STATISTICAL SIGNIFICANCE; UNCONSCIOUSNESS;

ADOLESCENT; ADULT; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPAIN; YOUNG ADULT;

EID: 44849118795     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01783.x     Document Type: Article

References (28)

1. Krop JS, Saudek CD, Weller WE, Powe NR, Shaffer T, Anderson GF. Predicting expenditures for Medicare beneficiaries with diabetes: a prospective cohort study from 1994 to 1996. Diabetes Care 1999 22 : 1660 6.
2. Evans JM, MacDonald TM, Leese GP, Ruta DA, Morris AD. Impact of type 1 and type 2 diabetes on patterns and costs of drug prescribing: a population-based study. Diabetes Care 2000 23 : 770 4.
3. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 : 977 86.
4. The DCCT Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 1995 18 : 1468 78.
5. Palmer AJ, Weiss C, Sendi PP et al. The cost-effectiveness of different management strategies for type 1 diabetes: a Swiss perspective. Diabetologia 2000 43 : 13 26.
6. The DCCT Research Group. Lifetime benefits and costs of intensive therapy as practised in the Diabetes Control and Complications Trial. J Am Med Assoc 1996 276 : 1409 15.
7. The DCCT Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 1995 18 : 1415 27.
8. Anderson JH Jr., Brunelle RL, Koivisto VA, Pfützner A, Traufmann ME, Vignati L, DiMarchi R. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997 46 : 265 70.
9. Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson JH. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care 1997 20 : 1827 32.
10. Ramsey S, Willke R, Briggs A et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005 8 : 521 33.
11. Desgagne A, Castilloux AM, Angers JF, LeLorier J. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 1998 13 : 487 97.
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
13. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 28 : 103 17.
14. Cryer PE. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999 15 : 42 6.
15. Allicar MP, Megas F, Houzard S, Baroux A, Le Thai F, Augendre-Ferrante B. Frequency and costs of hospital stays for hypoglycaemia in France in 1995. Presse Med 2000 29 : 657 61.
16. Chase HP, Lockspeiser T, Peery B, Shepherd M, MacKenzie T, Anderson J, Garg SK. The impact of the diabetes control and the complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001 24 : 430 4.
17. Brunelle RL, Llewelyn JA, Anderson JH, Gale EA, Koivisto VA. Meta-analysis of the effect of insulin lispro on SH in patients with type 1 diabetes. Diabetes Care 1998 21 : 1726 31.
18. Chen K, Chang EY, Summers KH, Obenchain RL, Yu-Isenberg KS, Sun P. Comparison of costs and utilization between users of insulin lispro versus users of regular insulin in a managed care setting. J Manag Care Pharm 2005 11 : 376 82.
19. Hart WM, Espinosa C, Rovira J. A simulation model of the cost of the incidence of IDDM in Spain. Diabetologia 1997 40 : 311 8.
20. Costa B, Arroyo J, Sabaté A. The economics of pharmacotherapy for diabetes mellitus. Pharmacoeconomics 1997 11 : 139 58.
21. Pagano E, Brunetti M, Tediosi F, Garattini L. Cost of diabetes: a methodological analysis of the literature. Pharmacoeconomics 1999 15 : 583 95.
22. Pedersen-Bjergaard U, Pramming S, Heller SR et al. Severe hypoglycemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev 2004 20 : 479 86.
23. Ray JA, Valentine WJ, Secnik K et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 2005 21 : 1617 29.
24. Palmer AJ, Annemans L, Roze S et al. Cost-effectiveness of ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective. Nefrologia 2004 24 : 231 8.
25. Oliva J, Lobo F, Molina B, Monereo S. Direct healthcare costs of diabetes mellitus patients in Spain. Diabetes Care 2004 27 : 2616 21.
26. Cox DJ, Gonder-Frederick LA, Kovatchev BP, Julian DM, Clarke WL. Progressive hypoglycemia's impact on driving simulation performance. Diabetes Care 2000 23 : 163 70.
27. Tupola S, Rajantie J, Akerblom HK. Experience of severe hypoglycemia may influence both patients' and physicians' subsequent treatment policy of insulin-dependent diabetes mellitus. Eur J Pediatr 1998 157 : 625 7.
28. Nordfeldt S, Jonsson D. Short-term effects of severe hypoglycaemia in children and adolescents with type 1 diabetes. A cost-of-illness study. Acta Paediatr 2001 90 : 137 42.